摘要
目的:观察赫赛汀(Herceptin)治疗人类表皮生长因子受体2(Her-2)过度表达晚期乳腺癌的临床疗效。方法:将56例Her-2过度表达的晚期乳腺癌患者随机分成3组,其中组1为赫赛汀单药组(n=18),首次剂量为赫赛汀4 mg/kg静脉注射,以后改为每周2 mg/kg静脉注射,维持1年;组2(n=20)为联合化疗组,联合多西他赛75 mg/m2,每3周给药1次,维持至治疗结束。赫赛汀的用法为4 mg/kg静脉注射,共联合化疗治疗4次,4周期化疗结束后,每月维持治疗剂量4 mg/kg静脉注射,共4次;组3(n=18)为对照组给予常规化疗药物治疗。结果:1、2两组使用赫赛汀治疗的乳腺癌患者客观缓解率(RR)分别为50.0%和83.3%,肿瘤进展时间(TTP)分别为5.8个月和10.4个月,两个用药组临床疗效与对照组相比差异有统计学意义(P<0.05)。结论:赫赛汀单药和联合化疗治疗Her-2过度表达的晚期乳腺癌均有较好的临床疗效,其中赫赛汀联合化疗治疗乳腺癌效果更显著。
Objetive： To observe the efficacy and toxicity of Hereeptin in treating 56 patients with Her-2 positive breast cancer. Methods： 56 patients with Her-2 positive breast cancer were randomly divided into 3 groups. There were singleagent group, combined-group and control group. Single-agent group （n=18）, Herceptin was given 4 mg/kg, then 2 mg/kg, for 1 year;, Combined-group （n=20）, Docetaxel was given 75 mg/m2 every 3 week, and Herceptin was given 4 mg/kg. The patients accepted 4 times of chemotherapy in total. After the first chemotherapy, Hereeptin was keep on therapy every month with the dose of 4 mg/kg, and it was used in 4 times, too; Control group （n=20）, patients were given the general chemotherapy. Results： In the two groups of the therapy with Herceptin, objective remission rate of group 1 and group 2 was 50.0% and 83.3% respectively, and the TIP was 5.8 months and 10.4 months respectively. The clinical curative effects of the two groups using Herceptin were better than that of the control group, which had remarkable difference （P〈0.05） Conclusion： Both Herceptin in single agent and combined with the chemotherapy drug are effective in the treatment of Her-2 positive advanced breast cancer, and Herceptin combined chemotherapy could obtain more significant effect in treating breat cancer.
出处
《中国医药导报》
CAS
2011年第7期71-72,共2页
China Medical Herald
